Article:
Di Martino, E, Tomlinson, DC orcid.org/0000-0003-4134-7484, Williams, SV et al. (1 more author) (2016) A place for precision medicine in bladder cancer: targeting the FGFRs. Future Oncology, 12 (19). pp. 2243-2263. ISSN 1479-6694

https://doi.org/10.2217/fon-2016-0042



Figure 2. A. Distribution of *FGFR3* point mutations according to bladder tumour stage. B. FGFR3 protein expression in relation to mutation according to bladder tumour stage. Expression above that in normal urothelium is defined as "high" and the same or lower levels than normal urothelium as "low". Data is from a one-year cohort of patients from a single institution. Adapted from reference 51.